Buy Sell East India Pharmaceutical Unlisted Shares | Share Price I Planify
company-image

Unlisted Shares

PHYSICAL

East India Pharmaceutical Works Limited Essentials

East India Pharmaceutical Works Limited Growth

Compounded Sales Growth

1 Year

3 Year

6 Year

Compounded Profit Growth

1 Year

4 Year

6 Year

Return On Equity

2018

2021

2023

Highlights

image
  • First-of-their-kind Generic Drugs - East India Pharmaceutical Works developed several first-of-its-kind generic drugs in India, including the first indigenously developed antimalarial drug, the first generic version of metformin (anti-diabetic), and the first generic version of ramipril (anti-hypertensive). The company also has a strong pipeline of new products in development across various therapeutic areas. 
image
  • Revenue Growth - The company's revenue has experienced a substantial rise, climbing from ₹201.6 Cr in FY22 to ₹233.3 Cr in FY23, indicating a growth rate of 15.7%. Over the past five years, the company's revenue has consistently increased, achieving a compound annual growth rate (CAGR) of 9.03% from FY18 to FY23.
image
  • Profitability -The company's profitability has consistently lagged behind industry standards. The EBIT margin, which stood at 3.6% in FY18, decreased to 2.9% in FY23, reflecting a Compound Annual Growth Rate (CAGR) of -4.65%. Although the net profit margin slightly increased from 0.4% in FY18 to 0.7% in FY23, the overall profitability was notably affected in FY23. This decline can be attributed to the rise in operating and other costs, impacting the overall profitability of the business.
image
  • Investment Thesis - When comparing East India Pharmaceutical Works to industry peers, the average price-to-earnings (P/E) ratio is around 32.17x. After incorporating the respective discounts, the share price is estimated to be in the range of ₹57 to ₹61. Despite positive signals related to revenue growth and profitability, the company seems to be slightly overvalued. Additionally, the Indian Pharmaceutical Industry is dominated by established giants serving a similar target market, limiting potential opportunities for East India Pharmaceutical Works to thrive.

Business Rating

image
Managment
lock starlock starlock starlock starlock star
image
Accounting Practice
lock starlock starlock starlock starlock star
image
Profatibility
lock starlock starlock starlock starlock star
image
Solvency
lock starlock starlock starlock starlock star
image
Growth
lock starlock starlock starlock starlock star
image
Valuation
lock starlock starlock starlock starlock star
Over all Ratings
lock starlock starlock starlock starlock star
Recommendation
lock starlock starlock starlock starlock star

Our Team

See More

Quantity

Invest

, Min. Investment: ₹